Professional presence

Summary of Publications and Events (˜17 years, 2005 – Present) covering diverse Therapeutic Areas (Cardiovascular, Hematology, Immunology, Neuroscience, Oncology), Regulatory (ICH E9(R1)), Quantitative (Statistics (Bayesian, Frequentist)) and Leadership (Collaborative Approaches and Mindsets):

  • Book Chapter (1)
  • Manuscripts (21)
  • Short Review / Commentary (2)
  • Conference Organising Committee Member (3)
  • Session Chair (4)
  • Mastermind: Leadership (1)
  • Clubhouse Session (1)
  • Presentations (9)
  • Posters (12)
  • Acknowledgements (7)

List of conferences and masterminds

  • Conference: Member of the Program Committee for the Master Protocols and Complex Innovative Designs Conference, Nov 4, 2021, DIA, Member of the Program Committee for the Master Protocols and Complex Innovative Designs Conference
  • Conference: Member of the Program Committee for the Complex Innovative Designs Conference, Mar 1, 2020, DIA, Member of the Program Committee for the Complex Innovative Designs Conference
  • Mastermind: Feminine Leadership in Corporate Virtual Mastermind, Jan-Sep, 2020.
  • I co-launched and co-led a nine-month Feminine Leadership In Corporate Virtual Mastermind Jan-2020 (completed Sep-2020) for pioneering women in corporate leadership roles across industries and geographies who want to bring more feminine leadership into their own style and into their workplaces.
  • Over nine months we came together to engage in generative discussions about what feminine leadership looks like in practice, discover together how to engage workplace challenges with a feminine leadership approach, co-create new knowledge and ways of being, encourage and support one another to be bold in our pioneering, and of course celebrate every success.

List of books / book chapters

List of short reviews

List of publications

List of posters and presentations

  • Poster: Introducing the DIA New Tools subgroup & its work (available at missingdata.org.uk), May 2017, PSI 2017 Conference, Singh P, Akacha M, O’Kelly M, Xu L, Roger J, on behalf of the DIA Scientific Working Group on Missing Data New Tools Subgroup
  • Presentation: Adverse Drug Reaction (ADR) screening in clinical trials, Nov 29, 2016, Basel Biometric Section, BBS Seminar Safety monitoring during the life cycle of a drug, November 29, 2016, Adverse Drug Reaction (ADR) screening in clinical trialsSee publication
  • Poster: Pooled analysis of two randomized, double-blind trials comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer, 2016, ASCO, Kimberly Blackwell, Pedro Gascon, C. Michael Jones, Allen Nixon, Roumen Nakov, Pritibha Singh, Andriy Krendyukov, Nadia Harbeck, Pooled analysis of two randomized, double-blind trials comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer
  • Poster: A randomized, double-blind trial to compare the efficacy and safety of proposed biosimilar pegfilgrastim (LA-EP2006) with reference pegfilgrastim in patients with breast cancer (PROTECT1), 2015, San Antonio Breast Cancer Symposium, A randomized, double-blind trial to compare the efficacy and safety of proposed biosimilar pegfilgrastim (LA-EP2006) with reference pegfilgrastim in patients with breast cancer (PROTECT1)
  • Poster: Comparison of EP2006, a Filgrastim Biosimilar, to the Originator: a Phase III, Randomized, Double-Blind Clinical Study, 2015, NCNN, Kimberly L Blackwell, Vladimir Semiglazov, Dmitry Krasnozhon, Irina Davidenko, Lidia Nelyubina, Roumen Nakov, Gabor Stiegler, Pritibha Singh, Arnd Schwebig, Stefan Kramer, Nadia Harbeck
  • Poster: Proposed Biosimilar Pegfilgrastim (LA-EP2006) and Reference Pegfilgrastim for the Prevention of Neutropenia in Patients with Breast Cancer: A Randomized, Double-Blind Trial. Protect 2: Pegfilgrastim Randomized Oncology Trial, 2015, Ash 2015, Proposed Biosimilar Pegfilgrastim (LA-EP2006) and Reference Pegfilgrastim for the Prevention of Neutropenia in Patients with Breast Cancer: A Randomized, Double-Blind Trial. Protect 2: Pegfilgrastim Randomized Oncology Trial
  • Poster: Effect of Certolizumab Pegol Over 48 Weeks in Patients, Feb 2014, 69th Annual Meeting of The Canadian Rheumatology Association (CRA), Walter Maksymowych (University of Alberta, Edmonton);Robert Landewe (Amsterdam); Martin Rudwaleit (Berlin);Désirée van der Heijde (Leiden University Medical Center,Leiden); Maxime Dougados (Descartes University, Paris);Phillip Mease (Swedish Medical Center and University of Washington School of Medicine, Seattle); John Reveille (University of Texas Health Science Center at Houston, Houston, Houston); Jessica Walsh (Salt Lake City); Alan Kivitz (Harrisburg); Jürgen Braun (Rheumazentrum Ruhrgebiet, Herne); Atul Deodhar (Oregon Health and Science University, Portland); Christian Stach (Brussels); Bengt Hoepken (Brussels); Pritibha Singh (Brussels); Joachim Sieper (Charité Universitätesmedizin Berlin, Berlin), Effect of Certolizumab Pegol Over 48 Weeks in Patients
  • Poster: Brivaracetam bioavailability/bioequivalence comparison between 10, 50, 75 and 100 mg tablets and 100 mg intravenous bolus in healthy volunteers, 2014, 11th European Congress on Epileptology (ECE) in Stockholm, Sweden, Armel Stockis, Pritibha Singh, Jan Hartstra, Salah Hadi
  • Presentation: Effect of Certolizumab Pegol over 48 Weeks in Patients with Axial Spondyloarthritis, including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis, 2014, 2014 CRA Annual Scientific Meeting & AHPA Annual Meeting, W. P. Maksymowych (Presenter), R. Landewé, M. Rudwaleit, D. van der Heijde, M. Dougados, P. J. Mease, J. Reveille, J. Walsh, A. Kivitz, J. Braun, A. Deodhar, C. Stach, B. Hoepken, P. Singh, J. Sieper
  • Poster: An Open-label Study on Adding Rotigotine Treatment to Low Dose of Pramipexole or Ropinirole in Patients With Advanced Parkinson’s Disease, 2013, 17th International Congress of Parkinson’s Disease and Movement Disorders, JM Kim, SJ Chung, JW Kim, P Singh, L Bauer, S Thierfelder, BS Jeon, The Asia Pacific Rotigotine Add-on Study Group
  • Poster: An Open-label Study on Switching Therapy From Pramipexole or Ropinirole to Rotigotine Transdermal System in Subjects With Advanced-stage, Idiopathic Parkinson’s Disease, 2013, 17th International Congress of Parkinson’s Disease and Movement Disorders, JM Kim, SJ Chung, JW Kim, BS Jeon, P Singh, L Bauer, S Thierfelder, The Asia Pacific Rotigotine Switching Study Group
  • Poster: Long-Term Maintenance of Improvements in Patient-Reported Outcomes with Certolizumab Pegol in Patients with Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis: 48-Week Results – Rapid-axSpA Study, 2013, ISPOR-EU Meetingspublication descriptionSieper J, Kivitz A., van Tubergen A., Deodhar A., Coteur G., Singh P., Landewé R, Long-Term Maintenance of Improvements in Patient-Reported Outcomes with Certolizumab Pegol in Patients with Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis: 48-Week Results – Rapid-axSpA Study
  • Presentation: Effect of Certolizumab Pegol over 48 Weeks in Patients with Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non- Radiographic Axial Spondyloarthritis, 2013, 77th Annual meeting of the American College of Rheumatology (ACR) & 48th Annual meeting of the Association of Rheumatology Health Professionals (ARHP);publication descriptionR. Landewé (Presenter), M. Rudwaleit, D. van der Heijde, M. Dougados, P. J. Mease, J. Reveille, J. Walsh, A. Kivitz, W. P. Maksymowych, J. Braun, A. Deodhar, C. Stach, B. Hoepken, P. Singh, J. Sieper, Effect of Certolizumab Pegol over 48 Weeks in Patients with Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non- Radiographic Axial Spondyloarthritis
  • Presentation: Identification of a low phosphatase and tensin homolog (PTEN) high phosphatidylinositol-3 kinase (PI3K) β expressing subset of squamous non-small-cell lung cancer (NSCLC), 2011, World Conference Lung Cancer 2011, M. Cumberbatch, X. Tang, G. Beran, S. Luke, P. Singh, A. Kvist, S. Cosulich, P. D. Smith, C. Behrens, E. S. Kim, M. Warren, C. Womack, N. Gray, I. Wistuba, D. P. Blowers (Presenter), Identification of a low phosphatase and tensin homolog (PTEN) high phosphatidylinositol-3 kinase (PI3K) β expressing subset of squamous non-small-cell lung cancer (NSCLC)
  • Presentation: Factors associated with weight gain during olanzapine therapy in Chinese patients with schizophrenia: a post hoc subgroup analysis of a six-month observational study, 2009, Chinese Association of Psychiatry 2009, Qiu Qing Ang (Presenter), Ji Sheng Tang, Jing Ping Zhao, Jian Hu, Kai Da Jiang, Hui Chun Li, Ming Li, Gang Wang, Gao Hua Wang, Shi Ping Xie, Fu De Yang, Jin Bei Zhang, Pritibha Singh, Susanna Holt and Tamás Treuer
  • Presentation: Speaker at Careers Session and Judge for Poster Presentations, 2009, Young Statisticians Conference, I was one of the speakers at the Careers Session and also on the industry judging panel for the poster presentations
  • Presentation: Speaker at Careers Night, Sep 2008, Statistical Society of Australia. On May 8, the Canberra Branch held a very successful Careers Night on the Australian National University campus. Nine speakers from a variety of government agencies, academia and private enterprise spoke briefly about the nature of their work and important role statistics plays. Presentation: Speaker at Careers Night
  • Poster: A three-month observational study in patients with major depressive disorder: associations between painful physical symptoms and clinical outcomes in Taiwanese patients, 2008, Taiwanese Society of Psychiatry, Kuang-Peng Chen, Nan-Ying Chiu, Chaucer CH. Lin, Yu-Chih Shen, Yuh-Ming Hou, Chin-Bin Yeh, Wen-Chen Ouyang, Pritibha Singh, Victoria Reed, Phil Lee
  • Poster: Efficacy and Safety of Somatropin Treatment in Australian Children with Short Stature enrolled in GeNeSIS, 2007, APEG ASM Conference 2007, Maree Grant, Timothy Jones, Chris Cowell, Belinda Moore, Christine Rodda, Pritibha Singh, Renee Granger, Philippe Carriere Efficacy and Safety of Somatropin Treatment in Australian Children with Short Stature enrolled in GeNeSIS
  • Presentation: Influence of climate parameters on incidence of stroke across different regions of the world, 2006, Department of Statistics, University of Auckland. I presented my thesis which was an analysis of pooled data from an international collaborative effort (Stroke and Weather Collaboration). Data came from population based stroke studies conducted in:

    ■ Auckland (ARCOS Study I, II, II)
    ■ Melbourne (NEMESIS)
    ■ Perth (PCSS)
    ■ UK (Oxfordshire Stroke Study)
    ■ Northern Sweden (Monica Stroke Study)
  • Presentation: From data cleaning to data gleaning, 2005, Department of Statistics, University of Auckland. I presented my analysis on a project on data from the Hematology Department, Middlemore Hospital (NZ). Data was on patients with Polycythemia Vera, a rare disease characterized by the proliferation of cells (red blood cells)

List of acknowledgements

en_GBEnglish
en_GBEnglish